| J&J warns doctors of Doxil cancer-drug shortage Thu,21 Jul 2011 02:06 PM PDT Reuters - NEW YORK (Reuters) - Johnson & Johnson has cautioned doctors not to begin treatment with its Doxil cancer drug because of shortages of the medicine made by an outside manufacturer. Full Story |
| Edwards Lifesciences profit edges higher Thu,21 Jul 2011 01:15 PM PDT Reuters - CHICAGO (Reuters) - Edwards Lifesciences Corp on Thursday reported slightly higher second-quarter profit, led by increased sales of transcatheter heart valves in Europe.Full Story | |
| Edwards Lifesciences profit edges higher Thu,21 Jul 2011 01:14 PM PDT Reuters - CHICAGO (Reuters) - Edwards Lifesciences Corp on Thursday reported slightly higher second-quarter profit, led by increased sales of transcatheter heart valves in Europe.Full Story | |
 NEW YORK (Reuters Health) - Reservists returning from Iraq orAfghanistan may have more trouble adjusting to life at home than full-time soldiers do -- and that can take a toll on their mental well-being, a UK study finds. | |
| Benefit of MS drugs comes at steep price: study Thu,21 Jul 2011 12:16 PM PDT Reuters - NEW YORK (Reuters Health) - Drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost, according to a study out Wednesday. Full Story | |
 BOSTON (Reuters) - The authors of a high-profile study on genetic patterns tied to old age have retracted it after a piece of equipment used to analyze the genes was found to produce incorrect results, the journal Science said. | |
 WASHINGTON (Reuters) - The perception by teenagers and young adults that heavy cigarette smoking is a high-risk activity has declined in many states, according to a study on substance abuse and mental health released on Thursday. | |
| FDA panel OKs Edwards heart valve despite risks Thu,21 Jul 2011 09:24 AM PDT Reuters - GAITHERSBURG, Maryland (Reuters) - Edwards Lifesciences Corp's heart valve for patients deemed too sick to have open-heart surgery was approved by a Food and Drug Administration advisory panel on Wednesday, despite concerns that it could increase the risk of stroke. Full Story | |
 LONDON (Reuters) - European regulators have recommended restricting the use of GlaxoSmithKline's pandemic flu vaccine Pandemrix because of a potential risk of narcolepsy in children or adolescents. | |
| Ohio leads list of top 20 states with toxic air Thu,21 Jul 2011 08:29 AM PDT Reuters - WASHINGTON (Reuters) - People living in Ohio, Pennsylvania and Florida are most at risk in the United States from toxic emissions spewing from coal and oil-fired power plants, two leading American environmental groups said in a report on Wednesday. Full Story | |
| AstraZeneca not planning confirmatory Brilinta trial Thu,21 Jul 2011 06:57 AM PDT Reuters - LONDON (Reuters) - AstraZeneca Plc has no plans to run a clinical trial to confirm the reasons behind a discrepancy between the performance of its newly approved heart drug Brilinta in North America and other parts of the world. Full Story | |
| AstraZeneca shares jump as U.S. approves Brilinta Thu,21 Jul 2011 12:55 AM PDT Reuters - LONDON (Reuters) - AstraZeneca shares jumped 3.5 percent on Thursday, buoyed by U.S. approval for its new heart drug Brilinta as a rival to Plavix, the world's second-biggest selling medicine. Full Story | |
 NEW YORK (Reuters Health) - Shortness of breath and reduced fitness among some military veterans returning from Iraq and Afghanistan may be caused by lung damage from smoke, sandstorms and toxins, a new study suggests. | |
| Offer women mammograms from age 40: doctor's group Wed,20 Jul 2011 02:05 PM PDT Reuters - NEW YORK (Reuters Health) - Doctors should offer all women in their 40s the chance to get annual screenings for breast cancer, according to new guidelines from an organization of women's health professionals. Full Story | |
| Benefit of MS drugs comes at steep price: study Wed,20 Jul 2011 01:46 PM PDT Reuters - NEW YORK (Reuters Health) - Drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost, according to a study out Wednesday. Full Story |
No comments:
Post a Comment